Barclays lowered the firm’s price target on Surgery Partners (SGRY) to $31 from $32 and keeps an Equal Weight rating on the shares post the Q3 report. The firm says the company’s operating backdrop remains favorable, but “idiosyncratic challenges slightly extend the free cash flow ramp.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $34 from $35 at Macquarie
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 25c
- Surgery Partners sees FY24 revenue greater than $3.075B, consensus $3.09B
- SGRY Earnings Report this Week: Is It a Buy, Ahead of Earnings?